Skip to content

Identifying Patients With Suspicion of Infection in the ED Who Have Low Disease Severity Using MR-proADM - Pilot Study

Identifying Patients With Suspicion of Infection in the ED Who Have Low Disease Severity Using Midregional Proadrenomedullin (MR-proADM) - Pilot Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03770533
Acronym
IDEAL
Enrollment
200
Registered
2018-12-10
Start date
2018-12-14
Completion date
2019-12-11
Last updated
2019-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients Presenting With Suspicion of Infection to the ED

Brief summary

Emergency departments (ED) are becoming increasingly over-crowded, with patients facing prolonged waiting times. Therefore, a safe and rapid assessment that identifies patients with low severity that could be treated as outpatients is essential for improving the workflow within the ED. The rationale of this IDEAL study is to provide guidance to safely decrease the number of hospital admissions through identification of low risk patients with the biomarker MR-proADM. This will be tested in a pilot study first.

Interventions

OTHERMR-proADM guided

MR-proADM value together with routine clinical evaluation identifies patients with a low 14 day mortality risk who do not need to be hospitalized

Sponsors

Brahms AG
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Consecutive patients presenting to the ED with suspicion of infection * Age ≥18 years * Written Informed Consent obtained

Exclusion criteria

* Recent major trauma or surgery * End stage renal failure requiring dialysis * Terminal disease and/or very severe medical co-morbidity where death has to be expected in the next 6 months, e.g. due to malignancy, cardiac, renal or hepatic failure * Patients those source of infection always requires hospital admission or never requires hospital admission. * Patients who cannot be discharged for other than medical reasons * Patient participates in any other interventional clinical trial * Patients with active intravenous drug use * Pregnant or lactating women * Patients who are institutionalized by official or judicial order * Dependents of the sponsor, the CRO, the study site or the investigator

Design outcomes

Primary

MeasureTime frame
Rate of patients admitted to the hospital14 days

Secondary

MeasureTime frame
28 days all-cause hospital re-admission (corrected for mortality)28 days
Number of patients re-presenting to the ED within 28 days28 days

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 23, 2026